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Background: A phase 3 randomized clinical trial was designed to test whether bardoxolone methyl, a
nuclear factor erythroid-2erelated factor 2 (Nrf2) activator, slows progression to end-stage renal disease
in patients with stage 4 chronic kidney disease and type 2 diabetes mellitus. The trial was terminated
because of an increase in heart failure in the bardoxolone methyl group; many of the events were clinically
associated with fluid retention.
Methods and Results: We randomized 2,185 patients with type 2 diabetes mellitus (T2DM) and stage 4
chronic kidney disease (CKD) (estimated glomerular filtration rate 15 to !30 mL min1 1.73 m2) to
once-daily bardoxolone methyl (20 mg) or placebo. We used classification and regression tree analysis
to identify baseline factors predictive of heart failure or fluid overload events. Elevated baseline B-type
natriuretic peptide and previous hospitalization for heart failure were identified as predictors of heart
failure events; bardoxolone methyl increased the risk of heart failure by 60% in patients with these risk
factors. For patients without these baseline characteristics, the risk for heart failure events among
bardoxolone methyle and placebo-treated patients was similar (2%). The same risk factors were also
identified as predictors of fluid overload and appeared to be related to other serious adverse events.
Conclusions: Bardoxolone methyl contributed to events related to heart failure and/or fluid overload in a
subpopulation of susceptible patients with an increased risk for heart failure at baseline. Careful selection
of participants and vigilant monitoring of the study drug will be required in any future trials of bardoxolone
methyl tomitigate the risk of heart failure andother serious adverse events. (JCardiacFail 2014;20:953e958)
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953Bardoxolone methyl and its analogues are oleanolic
acidederived synthetic triterpenoid compounds that
potently induce the nuclear factor erythroid-2erelated
factor 2 (Nrf2)eKeap1 pathway.1,2 Through interaction
with the Nrf2 repressor molecule, Keap1, bardoxolone
methyl promotes translocation of Nrf2 to the nucleus,
where it binds to antioxidant response elements in the
promoter region of its target genes, leading to induction
of many antioxidant and cytoprotective enzymes and
related proteins.3,4 Bardoxolone methyl is also a potent
inhibitor of the nuclear factor kB inflammatory pathway
through both direct (ie, inhibition of IKKb kinase activity)
and indirect (ie, detoxification of reactive oxygen species)
mechanisms.5 Because of this dual mechanism of action,
bardoxolone methyl is hypothesized to have therapeutic
potential in a variety of disease settings involving oxidative
stress and inflammation.
954 Journal of Cardiac Failure Vol. 20 No. 12 December 2014Preclinical studies have shown that bardoxolone methyl
and close analogues have activity in animal models of
kidney disease, including amelioration of murine ischemic
acute kidney injury,1 attenuation of renal interstitial
inflammation and fibrosis in mice with proteinuria induced
by protein overload,6,7 and protection against fibrosis in a
5/6 nephrectomy model of chronic kidney disease
(CKD).8 Several phase 2 clinical trials have demonstrated
that bardoxolone methyl lowers serum creatinine concen-
tration, along with other markers of kidney function
(eg, urea nitrogen, uric acid). A phase 2, double-blind,
randomized, placebo-controlled trial enrolling patients
with type 2 diabetes mellitus (T2DM) and mild to moderate
CKD showed these effects to be sustained for 52 weeks.9
On the basis of these data, we initiated a multinational,
randomized, double-blind, placebo-controlled phase 3
outcomes trial in patients with T2DM and stage 4 CKD:
Bardoxolone Methyl Evaluation in Patients with Chronic
Kidney Disease and Type 2 Diabetes: The Occurrence of
Renal Events (BEACON).
The BEACON trial was terminated for safety concerns;
the primary reason for study termination was an excess in
heart failure events, many occurring soon after bardoxolone
methyl treatment was started. We conducted a series of post
hoc analyses attempting to identify risk factors for heart
failure and fluid overload in the BEACON population.
Materials and Methods
Previous publications have described the BEACON trial design,
patient demographics, and baseline characteristics.10e12 Briefly,
2,185 patients with T2DM and stage 4 CKD were randomized
1:1 to once-daily administration of bardoxolone methyl (20 mg)
or placebo. The primary efficacy outcome was the time to first
event in the composite outcome defined as end-stage renal disease
(ESRD; need for chronic dialysis, renal transplantation, or renal
death) or cardiovascular death. The study had 3 secondary efficacy
outcomes: 1) change in estimated glomerular filtration rate;
2) time-to-first hospitalization for heart failure or death due to
heart failure; and 3) time to first event in the composite outcome
consisting of nonfatal myocardial infarction, nonfatal stroke,
hospitalization for heart failure, or cardiovascular death. An
independent Events Adjudication Committee (EAC), blinded to
study treatment assignment, evaluated whether ESRD events,
cardiovascular events, strokes, and fatalities met prespecified
definitions of primary and secondary end points, as described in
the EAC charter.10 The study (ClinicalTrials.gov identifier
NCT01351675) was approved by Institutional Review Boards at
participating study sites and was conducted in accordance with
the Declaration of Helsinki.
Statistical Analysis
We used classification and regression tree (CART) analysis to
identify baseline factors predictive of adjudicated hospitalization
or death due to heart failure.13 We selected CART as the method
of choice because we did not want to limit the form of interaction
terms to those easily defined by logistic or similar regression
models. We constructed separate classification trees for patients
randomized to the placebo and bardoxolone methyl groups. Weevaluated the following baseline characteristics as potential risk
factors: urine albumin-to-creatinine ratio, serum creatinine,
B-type natriuretic peptide (BNP), age, prescription of inhibitors
of the renin-angiotensin-aldosterone system, and previous
hospitalization for heart failure. We used a 10-fold cross-
validation testing method and Gini splitting rule13 in tree
development and selected the best tree on the basis of minimum
cost, regardless of tree size and complexity. We handled missing
values of BNP by substituting surrogate splitters.13
In reviewing heart failure case reports (eg, hospital admission
notes) we observed that evidence of fluid overload often preceded
heart failure events. Because some fluid overload events might
have progressed to heart failure, we viewed fluid overload events
as potential predictors of a patient’s being hospitalized for heart
failure. Therefore, we also performed CART analyses to explore
baseline factors predictive of EAC-adjudicated heart failure events
or potential fluid overload events. The latter were not EAC
confirmed.
Fluid overload events were not collected on specific case report
forms; rather, they were collected on the general adverse event
forms. We identified preferred terms potentially related to fluid
overload with the use of terms in the standardized MedDRA
(v15.1) query (SMQ) of ‘‘cardiac failure’’ and several other key
words (detailed in the Appendix).14 From this list of potential fluid
overload events, we determined which preferred terms were most
likely to lead to an EAC-confirmed heart failure event by calcu-
lating the probability that a patient would report an identified
preferred term as a serious adverse event that started after the
1st dose of study drug and that preceded or occurred on the
same day as an EAC-confirmed heart failure event (Table 2). To
assess the sensitivity and specificity of the preferred terms used
to define fluid overload, we generated 4 definitions that included
preferred terms with probabilities reported of $80%, $70%,
$50%, and $30% of being followed by an EAC-confirmed heart
failure event. We used the 80% cutoff to maximize specificity and
therefore considered patients to have had a fluid overload event if
they reported a preferred term in the 80% fluid overload definition
as a post-treatment adverse event (serious or nonserious). For
example, 5 of the 6 patients (83%) who reported a serious adverse
event of acute pulmonary edema also reported an EAC-confirmed
heart failure event that started on or after this serious adverse
event; however, in our analyses we consider all 9 patients who
reported acute pulmonary edema (serious or nonserious) to have
had a fluid overload event.
We also used logistic regression as another method for
identifying risk factors. This approach led to the same risk factors
identified by CART; however, diagnostics showed that the models
were poor fits to the data, probably because they were unable to
capture the nature of the interaction among the risk factors.
We used the software package CART v7 (Salford Systems, San
Diego, California) to perform the analyses and SAS v9.2 to
perform logistic regression.Results
Overview of BEACON Results
An increase in heart failure events was the major finding
that led to the termination of BEACON: 96/1,088 patients
(8.8%) randomized to bardoxolone methyl versus 55/
1,097 patients (5.0%) randomized to placebo, correspond-
ing to a hazard ratio (HR) of 1.83 (95% confidence interval
Table 1. Primary and Secondary Outcomes and All-Cause Mortality for Bardoxolone Methyl (BARD) Versus Placebo (PBO)
Patients in BEACON Stratified by Baseline BNP Level and Earlier Hospitalization for Heart Failure
Event
All Patients
BNP #200 pg/mL, No Previous HF
Hospitalization
PBO (n 5 1,097) BARD (n 5 1,088) PBO (n 5 557) BARD (n 5 519)
Primary composite* 69 (6) 69 (6) 25 (5) 15 (3)
End-stage renal disease 51 (5) 43 (4) 20 (4) 8 (2)
Any cardiovascular death 19 (2) 27 (2) 6 (1) 7 (1)
Secondary compositey 86 (8) 139 (13) 23 (4) 27 (5)
Heart failurez 55 (5) 96 (9) 10 (2) 12 (2)
Fatal or nonfatal myocardial infarction 16 (1) 19 (2) 6 (1) 6 (1)
Fatal or nonfatal stroke 11 (1) 14 (1) 5 (1) 2 (!1)
All-cause deathx 31 (3) 44 (4) 8 (1) 11 (2)
Serious adverse events by primary system organ classjj
Blood and lymphatic system disorders 11 (1) 20 (2) 3 (1) 6 (1)
Cardiac disorders 84 (8) 124 (11) 25 (4) 32 (6)
Ear and labyrinth disorders 1 (!1) 3 (!1) 1 (!1) 1 (!1)
Endocrine disorders 1 (!1) 1 (!1) 1 (!1) 1 (!1)
Eye disorders 2 (!1) 3 (!1) 1 (!1) 1 (!1)
Gastrointestinal disorders 39 (4) 46 (4) 22 (4) 17 (3)
General disorders and administration site
conditions
20 (2) 29 (3) 6 (1) 5 (1)
Hepatobiliary disorders 8 (1) 4 (!1) 0 1 (!1)
Immune system disorders 0 2 (!1) 0 0
Infections and infestations 63 (6) 79 (7) 29 (5) 22 (4)
Injury, poisoning, and procedural
complications
17 (2) 19 (2) 2 (!1) 6 (1)
Investigations 2 (!1) 3 (!1) 1 (!1) 1 (!1)
Metabolism and nutrition disorders 42 (4) 51 (5) 18 (3) 12 (2)
Musculoskeletal and connective tissue
disorders
13 (1) 21 (2) 7 (1) 12 (2)
Neoplasms benign, malignant and
unspecified
10 (1) 11 (1) 5 (1) 3 (1)
Nervous system disorders 35 (3) 37 (3) 19 (3) 10 (2)
Psychiatric disorders 3 (!1) 3 (!1) 2 (!1) 2 (!1)
Renal and urinary disorders 71 (6) 52 (5) 27 (5) 11 (2)
Reproductive system and breast disorders 3 (!1) 2 (!1) 2 (!1) 0
Respiratory, thoracic, and mediastinal
disorders
32 (3) 43 (4) 13 (2) 12 (2)
Skin and subcutaneous tissue disorders 1 (!1) 4 (!1) 0 3 (1)
Surgical and medical procedures 0 2 (!1) 0 1 (!1)
Vascular disorders 18 (2) 20 (2) 10 (2) 8 (2)
Observed totals for number (%) of patients (intention-to-treat population) with Events Adjudication Committeeeconfirmed primary or secondary events
and serious adverse events occurring through the study drug termination date (October 18, 2012).
*Number of patients with a primary event (time to first event in the composite end point of end-stage renal disease or cardiovascular death).
yNumber of patients with a secondary event (time to first event in the composite end point of nonfatal myocardial infarction, nonfatal stroke, hospitalization
for heart failure, or cardiovascular death).
zIncludes hospitalizations or deaths due to heart failure.
xTotals for all-cause death include all events occurring through the end of follow-up.
jjTotals include only serious adverse events (SAEs) with onset dates #30 days after a patient’s last dose of the study drug. Patients with multiple SAEs are
represented only once within each primary system organ class.
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observed in the bardoxolone methyl group occurred within
the 1st 4 weeks after randomization. After this initial
period, the Kaplan-Meier time-to-event curves for both
treatment groups remained roughly parallel.10
From randomization to the end of follow-up, 44 patients
(4.0%) in the bardoxolone methyl group and 31 (2.8%) in
the placebo group died (HR 1.47, 95% CI 0.93e2.32;
P 5 .11). Approximately two-thirds of the deaths (49 of
75 deaths) were cardiovascular in nature (29 bardoxolone
methyl versus 20 placebo; HR 1.44, 95% CI 0.80e2.59;
P 5 .23). Of the 49 cardiovascular deaths, the EAC classi-
fied 5 deaths in the bardoxolone methyl group and 1 in the
placebo group as due to heart failure.Risk Factors Associated With Adjudicated Heart
Failure and Fluid Overload Events
Baseline BNP and previous hospitalization for heart fail-
ure were identified as the only baseline factors associated
with EAC-confirmed heart failure events in bardoxolone
methyle and placebo-treated patients. Among patients
with previous hospitalization for heart failure or BNP
Ow200 pg/mL, treatment with bardoxolone methyl
increased the risk of heart failure by 60% (Fig. 1).
Conversely, among patients with no previous heart failure
hospitalizations or a baseline BNP level !w200 pg/mL,
the risk of heart failure was relatively low and similar
(2.0%) in the bardoxolone methyl and placebo groups.
Table 2. Fluid Overload Serious Adverse Events (SAEs) That Are Potentially Predictive of Heart Failure (HF) Events
Investigator-Reported Events
Classified by MedDRA
Preferred Term SAEs, n
Patients (n 5 2,185)
Reporting SAEs, n (%)
Proportion Whose Event
Preceded or Occurred on day
of EAC HF,* n/N (%)
Patients (n 5 2,185)
Reporting Event (SAE or
Non-SAE), n (%)
Right ventricular failurey 2 2 (!1) 2/2 (100) 2 (!1)
Cardiogenic shocky 1 1 (!1) 1/1 (100) 1 (!1)
Cardiomegalyy 1 1 (!1) 1/1 (100) 11 (1)
Hypervolemiay 1 1 (!1) 1/1 (100) 4 (!1)
Left ventricular failurey 1 1 (!1) 1/1 (100) 5 (!1)
Cardiac failure congestivey 128 99 (5) 85/99 (86) 139 (6)
Acute pulmonary edemay 6 6 (!1) 5/6 (83) 9 (!1)
Cardiac failure 15 13 (1) 10/13 (77) 18 (1)
Edema peripheral 13 11 (1) 8/11 (73) 406 (19)
Pulmonary edema 8 8 (!1) 5/8 (63) 19 (1)
Dyspnea 21 20 (1) 12/20 (60) 220 (10)
Cardiac failure chronic 5 5 (!1) 3/5 (60) 6 (!1)
Fluid overload 16 14 (1) 8/14 (57) 48 (2)
Cardiac failure acute 2 2 (!1) 1/2 (50) 4 (!1)
Diastolic dysfunction 2 2 (!1) 1/2 (50) 7 (!1)
Pericardial effusion 2 2 (!1) 1/2 (50) 6 (!1)
Generalized edema 4 3 (!1) 1/3 (33) 21 (1)
Pneumonia (not known to be
infectious)
39 35 (2) 10/35 (29) 68 (3)
Pleural effusion 7 6 (!1) 1/6 (17) 18 (1)
Angioedema 4 4 (!1) 0/4 6 (!1)
Left ventricular dysfunction 1 1 (!1) 0/1 6 (!1)
Lobar pneumonia 1 1 (!1) 0/1 1 (!1)
Pulmonary congestion 1 1 (!1) 0/1 13 (1)
Scan myocardial perfusion
abnormal
1 1 (!1) 0/1 1 (!1)
EAC, Events Adjudication Committeeeconfirmed.
*Proportion of patients whose fluid overload event preceded or occurred on the same day as an Events Adjudication Committeeeconfirmed heart failure
event out of the total number of patients reporting the fluid overload event.
yIncluded in the 80% cutoff fluid overload definition.
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included a composite of heart failure and fluid overload
events also identified elevated baseline BNP and previous
hospitalization for heart failure as predictors. More specif-
ically, for patients who had previous hospitalizations for
heart failure or a BNP level Ow200 pg/mL, treatment
with bardoxolone methyl increased the risk of heart failure
or fluid overload by 50% (Fig. 2).
Post hoc exclusionof patientswith these risk factors yielded
a population (519 bardoxolone methyl and 557 placebo pa-
tients) in which there would have been little differenceFig. 1. Classification tree for heart failure (HF) events in the BEACON tr
were confirmed by the Event Adjudication Committee (EAC). Classific
bardoxolone methyl (left) or placebo (right) and used the following base
assignment, baseline urine albumin-to-creatinine ratio, 1/serum creatinin
converting enzyme or angiotensin receptor blocker use, and previous hbetween treatment groups for serious adverse events and
adjudicated primary and secondary end point events (Table 1).
To investigate whether exposure to bardoxolone methyl
was associated with heart failure events, we used a pharma-
cokinetic model based on several earlier studies conducted
with bardoxolone methyl.15 We obtained population phar-
macokinetic sampling in 995/1,088 (91%) bardoxolone
methyletreated patients. No significant difference in
exposure (based on serum concentrations of bardoxolone
methyl) was noted in patients who experienced heart failure
and those who did not (Fig. 3; P 5 .12).ial. Analyses include only hospitalizations or deaths due to HF that
ation trees were constructed for all randomized patients receiving
line characteristics as potential risk factors: randomized treatment
e, B-type natriuretic peptide (BNP), age, concomitant angiotensin-
ospitalization for HF.
Fig. 2. Classification tree for fluid overload or HF events in the BEACON trial. Analyses include EAC-confirmed HF events or fluid
overload (FO) events, which were defined as post-randomization adverse events (serious and nonserious) for which $80% of subjects
who reported the event also experienced an EAC-confirmed HF. Classification trees were constructed for all randomized patients receiving
bardoxolone methyl (left) or placebo (right) and used the following baseline characteristics as potential risk factors: randomized treatment
assignment, baseline urine albumin-to-creatinine ratio, 1/serum creatinine, BNP, age, concomitant angiotensin-converting enzyme or
angiotensin receptor blocker use, and previous hospitalization for HF. Abbreviations as in Figure 1.
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The phase 3 randomized placebo-controlled trial of
bardoxolone methyl in patients with T2DM and stage 4
CKD showed a significantly increased risk of heart failure
events. No increased risk of heart failure or fluid retention
with bardoxolone methyl had been observed in previous
phase 1 and phase 2 trials, but those trials were much
smaller than BEACON. Moreover, whereas most of the
patients in previous trials had stage 3 CKD, BEACONFig. 3. Analysis of bardoxolone methyl exposures in patients with
and without HF (intention-to-treat population). Apparent post hoc
clearance estimates with the use of NONMEM were used to
calculate bardoxolone methyl area under the receiver operating
characteristic curve concentrations at steady state (AUCSS). Box
plots include median (middle line), 25th and 75th quartiles (lower
and upper bounds of boxes), and outlier AUCSS values (ng$h/mL)
for bardoxolone methyl patients with pharmacokinetic data.
AUCSS values for bardoxolone methyl patients with EAC-
confirmed HF events through the study drug termination date
(October 18, 2012) were compared with bardoxolone methyl
patients without events. Abbreviations as in Figure 1.limited enrollment to patients with T2DM and stage 4
CKD, a population known to be at higher risk for cardiovas-
cular events.
Two major risk factors were shown to predict heart failure
events in BEACON: baseline BNPOw200 pg/mL and pre-
vious hospitalization for heart failure, both recognized risk
factors for heart failure hospitalization and death in other
populations.16e18 BNP had not been assessed in any previous
trial conducted with bardoxolone methyl. CART analyses
that included a composite of heart failure and fluid overload
events identified the same risk factors. These results suggest
that bardoxolone methyl increased the risk of heart failure
principally in an identifiable subpopulation of patients.
Area under the receiver operating characteristic curve con-
centrations of bardoxolone methyl did not distinguish bar-
doxolone methyletreated patients who experienced heart
failure from those who did not, suggesting that the dose,
formulation, and frequency of administration did not materi-
ally contribute to the observed increase in risk. Additionally,
in the BEACON substudy, bardoxolone methylestreated pa-
tients had a meaningful reduction in urine volume and
sodium excretion at week 4 relative to baseline, and
preclinical studies had demonstrated that bardoxolone
methyl modulates endothelin expression in the kidneys.19
These data suggest that throughmodulation of the endothelin
pathway, bardoxolone methyl may pharmacologically pro-
mote acute sodium and volume retention. Thus, retention
of fluid from bardoxolone methyl treatment may have trans-
lated to frank fluid overload and heart failure in susceptible
patients with recognized risk factors at baseline. Notably,
in patientswithout these baseline risk factors for heart failure,
bardoxolone methyl did not increase the occurrence of heart
failure or fluid overload compared with placebo.
Although the primary intention of the analyses was to
identify risk factors associated with heart failure and fluid
overload, these same risk factors may have contributed to
other safety-related imbalances observed in BEACON.
Events such as lower respiratory tract infection, edema,
and anemia can be associated with (or mistaken for) fluid
overload and heart failure. Whether these findings reflect
958 Journal of Cardiac Failure Vol. 20 No. 12 December 2014the uncertainties associated with adverse event reporting
(noncardiovascular, renal, or neurologic events that were
not adjudicated) or a true susceptibility to other adverse
outcomes is unknown. Although patients with normal or
near normal BNP and no history of heart failure did not
experience an increased risk of adverse events, these
characteristics are common in patients with T2DM and
stage 4 CKD. Had we excluded patients on the basis of
either of these characteristics, the BEACON population
would have been reduced by roughly one-half.
The CART and pharmacokinetic analyses presented here
cannot fully explain the findings observed in BEACON.
Nevertheless, posteclinical trial ‘‘forensics’’ can help us
design better, smarter clinical trials in the future. Any future
trials of bardoxolone methyl in other patient populations
will require careful selection of study patients to mitigate
the risk of heart failure and other serious adverse events.
Disclosures
G.L.B. was a member of the BEACON Steering
Committee and is a consultant for Abbvie and Reata.
G.M.C. was the chair of the BEACON Steering Committee
and has received research support from Reata. D.d.Z. was
the chair of the BEACON Steering Committee and is a
consultant for and has received honoraria from Abbvie
and Reata. P.A.M. was the chair of the BEACON
Independent Data Monitoring Committee and is a
consultant for Reata. J.J.M. was a member of the BEACON
Steering Committee and is a consultant for and received
honoraria from Reata. J.W. is consultant for and has
received fees and honoraria from Reata. Her company,
Statistics Collaborative, served as the statistical group for
the BEACON study. D.W. is employed by Statistics
Collaborative. M.P.C., A.G., and C.J.M. are employed by
and have a financial interest in Reata. P.G.L. is employed
by and has a financial interest in Abbvie.Supplementary Data
Supplementary data related to this article can be found at
http://dx.doi.org/10.1016/j.cardfail.2014.10.001References
1. Wu QQ, Wang Y, Senitko M, Meyer C, Wigley WC, Ferguson DA,
et al. Bardoxolone methyl (BARD) ameliorates ischemic AKI and in-
creases expression of protective genes Nrf2, PPARg, and HO-1. Am J
Physiol Renal Physiol 2011;300:F1180e92.
2. Lee D-F, Kuo H-P, Liu M, Chou C-K, Xia W, Du Y, et al. KEAP1 E3
ligaseemediated downregulation of NF-kappaB signaling by targeting
IKKbeta. Mol Cell 2009;36:131e40.3. Dinkova-Kostova AT, Liby KT, Stephenson KK, Holtzclaw WD,
Gao X, Suh N, et al. Extremely potent triterpenoid inducers of the
phase 2 response: correlations of protection against oxidant and in-
flammatory stress. Proc Natl Acad Sci U S A 2005;102:4584e9.
4. Osburn WO, Kensler TW. Nrf2 signaling: an adaptive response
pathway for protection against environmental toxic insults. Mutat
Res 2008;659:31e9.
5. Chin M, Lee C-YI, Chuang J-C, Bumeister R, Wigley WC, Sonis ST,
et al. Bardoxolone methyl analogs RTA 405 and dh404 are well toler-
ated and exhibit efficacy in rodent models of Type 2 diabetes and
obesity. Am J Physiol Ren Physiol 2013;304:F1438e46.
6. Ma R, Bumeister R, Stidham R. Bardoxolone methyl (BARD) inhibits
inflammatory signaling in cultured mesangial cells. Proceedings of the
National Kidney Foundation Spring Clinical Meetings, April 13-17,
2010, Lake Buena Vista, FL.
7. Ding Y, Stidham RD, Bumeister R, Trevino I, Winters A, Sprouse M,
et al. The synthetic triterpenoid, RTA 405, increases the glomerular
filtration rate and reduces angiotensin II-induced contraction of
glomerular mesangial cells. Kidney Int 2013;83:845e54.
8. Aminzadeh MA, Reisman SA, Vaziri ND, Khazaeli M, Yuan J,
Meyer CJ. The synthetic triterpenoid RTA dh404 (CDDO-dhTFEA)
restores Nrf2 activity and attenuates oxidative stress, inflammation,
and fibrosis in rats with chronic kidney disease. Xenobiotica 2014;
44:570e8.
9. Pergola PE, Raskin P, Toto RD, Meyer CJ, Huff JW, Grossman EB,
et al. Bardoxolone methyl and kidney function in CKD with type 2
diabetes. N Engl J Med 2011;365:327e36.
10. de Zeeuw D, Akizawa T, Audhya P, Bakris GL, Chin M, Christ-
Schmidt H, et al. Bardoxolone methyl in type 2 diabetes and stage 4
chronic kidney disease. N Engl J Med 2013;369:2492e503.
11. de Zeeuw D, Akizawa T, Agarwal R, Bakris GL, Chin M, Krauth M,
et al. Rationale and trial design of Bardoxolone Methyl Evaluation in
Patients With Chronic Kidney Disease and Type 2 Diabetes: The
Occurrence of Renal Events (BEACON). Am J Nephrol 2013;37:
212e22.
12. Lambers Heerspink HJ, Chertow G, Akizawa T, Audhya P, Bakris GL,
Goldsberry A, et al. Baseline characteristics in the Bardoxolone
Methyl Evaluation in Patients With Chronic Kidney Disease and
Type 2 Diabetes Mellitus: The Occurrence of Renal Events (BEA-
CON) trial. Nephrol Dial Transplant 2013;28:2841e50.
13. Breiman L, Friedman JH, Olshen RA, Stone CJ. Classification and
regression trees. Boca Raton: CRC Press; 1984. p. 368.
14. Mann JFE, Green D, Jamerson K, Ruilope LM, Kuranoff SJ, Littke T,
et al. Avosentan for overt diabetic nephropathy. J Am Soc Nephrol
2010;21:527e35.
15. Klein C, Noertersheuser P, Mensing S, Teuscher N, Meyer C,
Dumas E, et al. Exposure-response analyses of bardoxolone methyl
safety and efficacy and clinical trial simulations to inform phase III
dose selection. Nephrol Dial Transplant 2012;27:ii403.
16. Vinson JM, Rich MW, Sperry JC, Shah AS, McNamara T. Early
readmission of elderly patients with congestive heart failure. J Am
Geriatr Soc 1990;38:1290e5.
17. McCullough PA, Nowak RM, McCord J, Hollander JE, Hermann HC,
Steg PG, et al. B-Type natriuretic peptide and clinical judgment in
emergency diagnosis of heart failure: analysis from Breathing Not
Properly (BNP) multinational study. Circulation 2002;106:416e22.
18. De Lemos JA, McGuire DK, Drazner MH. B-Type natriuretic peptide
in cardiovascular disease. Lancet 2003;362:316e22.
19. Chin M, Reisman S, Bakris G, O’Grady M, Linde PG,
McCullough PA, et al. Mechanisms contributing to adverse cardiovas-
cular events in patients with type 2 diabetes mellitus and stage 4
chronic kidney disease treated with bardoxolone methyl. Am J Neph-
rol 2014;39:499e508.
